IRIS
PERNO, CARLO-FEDERICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 138.921
AS - Asia 12.520
EU - Europa 12.260
SA - Sud America 2.336
AF - Africa 290
OC - Oceania 127
Continente sconosciuto - Info sul continente non disponibili 44
Totale 166.498
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 138.587
SG - Singapore 6.542
CN - Cina 2.134
DE - Germania 2.054
BR - Brasile 1.944
UA - Ucraina 1.865
HK - Hong Kong 1.385
IT - Italia 1.384
SE - Svezia 1.334
IE - Irlanda 1.220
RU - Federazione Russa 1.105
FR - Francia 764
PL - Polonia 721
GB - Regno Unito 716
KR - Corea 698
VN - Vietnam 561
FI - Finlandia 499
IQ - Iraq 238
CA - Canada 189
IN - India 157
ID - Indonesia 146
AR - Argentina 141
AU - Australia 124
JP - Giappone 120
NL - Olanda 115
BE - Belgio 103
AT - Austria 99
ZA - Sudafrica 90
MX - Messico 87
TR - Turchia 80
ES - Italia 78
BD - Bangladesh 77
EC - Ecuador 77
CZ - Repubblica Ceca 66
IR - Iran 65
PK - Pakistan 57
CL - Cile 38
CO - Colombia 37
EU - Europa 34
UZ - Uzbekistan 34
PH - Filippine 33
CM - Camerun 32
MA - Marocco 31
VE - Venezuela 31
AE - Emirati Arabi Uniti 29
CH - Svizzera 24
PY - Paraguay 24
EG - Egitto 23
KE - Kenya 23
PE - Perù 20
LT - Lituania 19
IL - Israele 16
NP - Nepal 16
RO - Romania 16
KZ - Kazakistan 15
TN - Tunisia 15
KG - Kirghizistan 13
SA - Arabia Saudita 13
BG - Bulgaria 12
JO - Giordania 12
UY - Uruguay 12
BO - Bolivia 11
GR - Grecia 11
AZ - Azerbaigian 10
DZ - Algeria 10
JM - Giamaica 10
MY - Malesia 10
DM - Dominica 8
NG - Nigeria 8
PT - Portogallo 8
CR - Costa Rica 7
DK - Danimarca 7
DO - Repubblica Dominicana 7
ET - Etiopia 7
GH - Ghana 7
HU - Ungheria 7
LB - Libano 7
PS - Palestinian Territory 7
A2 - ???statistics.table.value.countryCode.A2??? 6
AL - Albania 6
OM - Oman 6
TT - Trinidad e Tobago 6
TW - Taiwan 6
BY - Bielorussia 5
CI - Costa d'Avorio 5
LK - Sri Lanka 5
LY - Libia 5
QA - Qatar 5
RS - Serbia 5
UG - Uganda 5
AO - Angola 4
GE - Georgia 4
GT - Guatemala 4
HN - Honduras 4
MN - Mongolia 4
PA - Panama 4
TZ - Tanzania 4
BN - Brunei Darussalam 3
BW - Botswana 3
CG - Congo 3
Totale 166.438
Salva come PNG Salva come JPEG
Città #
Woodbridge 41.750
Wilmington 36.808
Houston 32.035
Fairfield 3.939
Ann Arbor 3.352
Singapore 3.052
Ashburn 2.217
Chandler 1.981
Jacksonville 1.676
Seattle 1.658
Hong Kong 1.371
Cambridge 1.356
Dublin 1.152
Beijing 1.054
Medford 911
Dearborn 668
Kraków 626
Santa Clara 612
Rome 498
Los Angeles 435
Lawrence 429
New York 426
Dallas 417
Moscow 403
The Dalles 367
Mülheim 270
Buffalo 242
San Diego 208
Menlo Park 206
São Paulo 200
Council Bluffs 196
Milan 195
Ho Chi Minh City 171
Zhengzhou 160
Munich 150
Hanoi 129
Nuremberg 120
Jakarta 113
Boardman 106
Falls Church 106
London 104
Brussels 98
Phoenix 96
Chicago 90
University Park 86
San Francisco 82
Helsinki 79
Redwood City 79
Dong Ket 78
Palo Alto 76
Norwalk 75
San Jose 74
Guangzhou 68
Mountain View 65
Warsaw 64
Redondo Beach 63
San Mateo 62
Tokyo 62
Baghdad 61
Nanjing 60
Rio de Janeiro 60
Creede 59
Toronto 59
Verona 57
Orem 56
Columbus 54
Shanghai 53
Denver 46
Johannesburg 46
Poplar 45
Chennai 44
Saint Petersburg 44
Brooklyn 43
Montreal 43
Hefei 42
Vienna 41
Amsterdam 40
Atlanta 40
Kunming 40
North Bergen 39
Boston 35
Belo Horizonte 34
Melbourne 34
Stockholm 34
Lappeenranta 33
Sulaymaniyah 33
Sydney 33
Brasília 32
Brno 31
Curitiba 31
Olomouc 31
Colorado Springs 30
Canberra 29
Guayaquil 29
Jinan 29
Nanchang 27
Frankfurt am Main 25
Seoul 25
Mexico City 24
Tashkent 24
Totale 144.841
Salva come PNG Salva come JPEG
Nome #
1,2,3-TRIAZOLE-[2',5'-BIS-O-(TERT-BUTYLDIMETHYLSILYL)-BETA-D-RIBOFURANOSYL]-3'-SPIRO-5''-(4''-AMINO-1'',2''-OXATHIOL 2'',2''-DIOXIDE) (TSAO) ANALOGS - SYNTHESIS AND ANTI-HIV-1 ACTIVITY 1.049
Antibiotic susceptibility of vancomyin and nitrofurantoin in Staphylococcus aureus isolated from burnt patients in Sulaimaniyah, Iraqi Kurdistan 736
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test 576
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes 557
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 557
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 550
Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase 532
KI and WU polyomaviruses and CD4+ cell counts in HIV-1-infected patients, Italy 530
Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy 526
Progesterone and Melanoma Cells: An Old Story Suspended between Life and Death 513
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 510
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 510
A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication 505
The novel swine-origin H1N1 influenza A virus riddle: is it a domestic bird H1N1-derived virus? 504
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev 501
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 493
Therapeutic strategies towards HIV-1 infection in macrophages 490
Carbohydrate-binding agents (CBAs) inhibit HIV-1 infection in human primary monocyte-derived macrophages (MDMs) and efficiently prevent MDM-directed viral capture and subsequent transmission to CD4(+) T lymphocytes 487
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 484
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 483
Virologic correlates of adherence to antiretroviral medications and therapeutic failure 481
Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso 481
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 479
Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes 477
A multi-targeted drug candidate with dual anti-HIV and anti-HSV activity 475
A multicenter evaluation of the Abbott RealTime HCV Genotype II assay 473
Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child 473
Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008 472
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 472
Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection 470
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 469
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 469
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 469
Activity of the (R)-Enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems 467
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 467
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 467
Thymosin α 1 potentiates the release by CD8(+) cells of soluble factors able to inhibit HIV-1 and human T lymphotropic virus 1 infection in vitro 467
Nucleotide polymorphisms in the 5'-UTR region of HCV can affect the ability of two widely used assays to assign an HCV genotype 466
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 466
Correlation between induction of lymphocyte apoptosis and prostaglandin E2 production by macrophages infected with HIV 465
Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection 464
Viral causes of influenza-like illness: Insight from a study during the winters 2004-2007 464
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 464
Understanding HIV compartments and reservoirs 463
Novel drug resistance mutations in HIV: Recognition and clinical relevance 462
Red blood cells mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to primary macrophages: Efficiency, metabolism and activity against human immunodeficiency virus or herpes simplex virus 461
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 461
HIV fitness and resistance as covariates associated with the appearance of mutations under antiretroviral treatment 460
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice 460
Thymosin alpha 1 and HIV-1: Recent advances and future perspectives 460
Influenza virus A (H5N1): A pandemic risk? 459
Immunomodulatory activity of 9-(2-phosphonyl-methoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models 459
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs 459
Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029 458
Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence 457
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues 457
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 456
Advances in macrophage and dendritic cell biology in HIV-1 infection stress key understudied areas in infection, pathogenesis, and analysis of viral reservoirs 454
HIV-1-associated dementia during HAART therapy 454
Molecular analysis based on mtLSU-rRNA and DHPS sequences of Pneumocystis jirovecii from immunocompromised and immunocompetent patients in Italy 454
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 454
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 454
Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines 453
Human immunodeficiency virus infection and acquired immunodeficiency syndrome dementia complex: Role of cells of monocyte-macrophage lineage 453
Macrophages and HIV infection: Therapeutical approaches toward this strategic virus reservoir 453
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 453
Identification of the novel KI polyomavirus in the respiratory tract of an Italian patient 451
Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: New therapeutic strategies 451
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 451
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 450
Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy 450
Primary macrophages infected by human immunodeficiency virus trigger CD95-mediated apoptosis of uninfected astrocytes 448
Nerve growth factor is an autocrine factor essential for the survival of macrophages infected with HIV 448
Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients 448
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 448
Effective program against mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso 448
Monitoring of KI and WU polyomaviruses in hematopoietic stem cell transplant patients 448
Glutathione inhibits HIV replication by acting at late stages of the virus life cycle 447
Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing. 446
Population dynamics of HIV-1 subtype B in a cohort of men-having-sex-with-men in Rome, Italy 445
Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed 444
Characterization of novel HIV drug resistance mutations using clustering, multidimensional scaling and SVM-based feature ranking 442
A boceprevir failure in a patient infected with HCV-genotype 1g: importance and limitations of virus genotyping prior to HCV protease inhibitor-based therapy 442
Telomerase activity, hTERT expression, and phosphorylation are downregulated in CD4(+) T lymphocytes infected with human immunodeficiency virus type 1 (HIV-1) 440
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study 440
Drug-loaded red blood cell-mediated clearance of HIV-1 macrophage reservoir by selective inhibition of STAT1 expression 438
Macrophage depletion induced by clodronate-loaded erythrocytes 438
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 438
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 437
HIV and cells of macrophage/dendritic lineage and other non-T cell reservoirs: new answers yield new questions 436
Excretion of the novel polyomaviruses KI and WU in the stool of patients with hematological disorders 435
Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD4+ T lymphocytes in hu-SCID mice 435
The novel KI, WU, MC polyomaviruses: possible human pathogens? 434
A case of Italian HIV-2 infection: a genetic analysis 434
Antiviral profile of HIV inhibitors in macrophages: Implications for therapy 433
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 433
Late-onset haemorrhagic cystitis in children after haematopoietic stem cell transplantation for thalassaemia and sickle cell anaemia: a prospective evaluation of polyoma (BK) virus infection and treatment with cidofovir (CDV) 433
Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin 432
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. 431
When and how to use maraviroc in HIV-infected patients 430
Totale 47.428
Salva come PNG Salva come JPEG
Categoria #
all - tutte 362.036
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 362.036
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20219.635 0 0 0 0 0 2.416 2.926 2.119 493 482 823 376
2021/20225.019 233 358 337 253 210 523 206 179 764 480 232 1.244
2022/20235.987 665 415 201 716 465 1.332 426 454 482 110 498 223
2023/20242.031 267 195 142 72 258 344 88 83 55 89 35 403
2024/202511.941 399 2.594 1.194 653 363 690 1.212 538 1.080 715 1.404 1.099
2025/20268.364 1.394 876 2.270 1.601 1.535 688 0 0 0 0 0 0
Totale 167.762